SinoMab BioScience EBITDA margin
Was ist das EBITDA margin von SinoMab BioScience?
EBITDA margin von SinoMab BioScience Limited ist 13,925.90%
Was ist die Definition von EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience
Was macht SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Unternehmen mit ebitda margin ähnlich SinoMab BioScience
- Horseshoe Metals hat EBITDA margin von 8,935.63%
- Kaili Resources hat EBITDA margin von 9,119.88%
- Red Sky hat EBITDA margin von 9,289.83%
- Exore Resources hat EBITDA margin von 10,362.46%
- Gold Reserve hat EBITDA margin von 10,882.26%
- Volt Resources hat EBITDA margin von 12,108.33%
- SinoMab BioScience hat EBITDA margin von 13,925.90%
- Satellos Bioscience Inc hat EBITDA margin von 13,993.40%
- Australian Vanadium hat EBITDA margin von 14,193.04%
- Australian Vanadium hat EBITDA margin von 14,193.04%
- Sprott Physical Gold Trust hat EBITDA margin von 14,706.31%
- Red Hill Iron hat EBITDA margin von 15,048.31%
- Transport of India hat EBITDA margin von 16,294.76%